Target Name: CD2
NCBI ID: G914
Other Name(s): CD2 variant 2 | Rosette receptor | CD2 molecule | erythrocyte receptor | LFA-2 | rosette receptor | SRBC | CD2 antigen (p50), sheep red blood cell receptor | T11 | T-cell surface antigen CD2 (isoform 1) | Lymphocyte-function antigen-2 | CD2 variant 1 | lymphocyte-function antigen-2 | T-cell surface antigen T11/Leu-5 | CD2 molecule, transcript variant 2 | Erythrocyte receptor | LFA-3 receptor | CD2 molecule, transcript variant 1 | CD2_HUMAN | T-cell surface antigen CD2 (isoform 2) | T-cell surface antigen CD2

CD2: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Introduction

CD2 (Complement receptor 2) is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and eyes. It plays a crucial role in the immune response by allowing white blood cells to recognize and destroy foreign particles, such as viruses and bacteria. CD2 has also been implicated in the development and progression of several chronic diseases, including multiple sclerosis, rheumatoid arthritis, and cancer. As a result, targeting CD2 has become an attractive research focus in recent years.

CD2 Variants and Therapeutic Potential

CD2 has four known variants, namely CD2A, CD2B, CD2C, and CD2D. These variants differ in expression levels and function. CD2A is the most common form of CD2 and is expressed in a variety of tissues, including lymph nodes, spleen, bone marrow, and platelets. CD2B is only expressed in skin and mucosal tissues. CD2C is expressed in glomerular epithelial cells and retinal tissue. CD2D is expressed in liver cells.

Although CD2 plays an important role in a variety of physiological processes, the roles of CD2 variants in disease vary. For example, loss of CD2A is associated with a variety of autoimmune diseases, including rheumatoid arthritis, autoimmune hepatitis, and some autoimmune nephritis. Loss of CD2B is associated with skin diseases and some cancers. Loss of CD2C is associated with glomerular disease and autoimmune nephritis. Loss of CD2D is associated with liver disease and certain cancers.

Therefore, studying CD2 variants and their relationship with diseases can provide us with new treatment ideas and targets.

CD2 as a Drug Target

CD2 variants are considered potential drug targets because they are expressed in a variety of diseases. In particular, loss of CD2A is associated with autoimmune diseases and some autoimmune nephritis. Therefore, researchers are exploring the anti-inflammatory and immunosuppressive effects of CD2A and investigating whether activation of CD2A can suppress immune responses and reduce inflammation.

CD2 variants are also associated with the development of cancer. For example, loss of CD2B is associated with skin diseases and certain cancers. Therefore, researchers are exploring the anti-tumor effects of CD2B and investigating whether activation of CD2B can inhibit the growth and spread of tumor cells.

CD2 as a Biomarker

In addition to their role in disease, CD2 variants may also serve as potential biomarkers. For example, loss of CD2A has been shown to be associated with a variety of autoimmune diseases. Therefore, researchers are exploring the application of CD2A detection and monitoring in disease diagnosis. In addition, loss of CD2B has been associated with the development of skin diseases and certain cancers. Therefore, researchers are exploring the application of CD2B detection and monitoring in disease diagnosis.

in conclusion

CD2 is a protein expressed in various tissues and plays an important role in the immune system and the occurrence of diseases. CD2 variants have different roles in diseases. Therefore, studying CD2 variants and their relationship with diseases can provide us with new treatment ideas and targets. In addition, CD2 variants may also be used as potential biomarkers for disease diagnosis. With further research, we may discover the important role of CD2 in the treatment of various chronic diseases.

Protein Name: CD2 Molecule

Functions: CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function

More Common Targets

CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34